{"id":3333,"date":"2020-12-14T07:30:23","date_gmt":"2020-12-14T07:30:23","guid":{"rendered":"http:\/\/dev.sunpharma.com\/?page_id=3333"},"modified":"2026-05-08T19:52:28","modified_gmt":"2026-05-08T14:22:28","slug":"investors-statutory-communications","status":"publish","type":"page","link":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","title":{"rendered":"Investors &#8211; Statutory Communications"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.16&#8243; background_image=&#8221;https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/investor-banner.jpg&#8221; parallax=&#8221;on&#8221; da_disable_devices=&#8221;off|off|off&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_fullwidth_header title=&#8221;Investor Information&#8221; header_fullscreen=&#8221;on&#8221; button_one_url=&#8221;#visionvalues&#8221; button_two_url=&#8221;#codeofconduct&#8221; _builder_version=&#8221;4.16&#8243; title_font=&#8221;|700|||||||&#8221; title_text_color=&#8221;#f7941e&#8221; title_font_size=&#8221;40px&#8221; title_line_height=&#8221;1.2em&#8221; content_font=&#8221;||||||||&#8221; content_text_color=&#8221;#000000&#8243; content_line_height=&#8221;1.8em&#8221; subhead_font=&#8221;||||||||&#8221; subhead_text_color=&#8221;rgba(0,0,0,0.6)&#8221; subhead_font_size=&#8221;22px&#8221; subhead_line_height=&#8221;1.4em&#8221; background_color=&#8221;rgba(255,255,255,0.7)&#8221; custom_button_one=&#8221;on&#8221; button_one_text_size=&#8221;20px&#8221; button_one_text_color=&#8221;#ffffff&#8221; button_one_bg_color=&#8221;#f7941e&#8221; button_one_border_width=&#8221;0px&#8221; button_one_font=&#8221;|||on|||||&#8221; button_one_use_icon=&#8221;off&#8221; custom_button_two=&#8221;on&#8221; button_two_text_size=&#8221;20px&#8221; button_two_text_color=&#8221;rgba(0,0,0,0.7)&#8221; button_two_bg_color=&#8221;#ffffff&#8221; button_two_border_width=&#8221;0px&#8221; button_two_font=&#8221;|||on|||||&#8221; button_two_use_icon=&#8221;off&#8221; button_two_custom_margin=&#8221;||||false|false&#8221; button_two_custom_margin_tablet=&#8221;&#8221; button_two_custom_margin_phone=&#8221;|||1px|false|false&#8221; button_two_custom_margin_last_edited=&#8221;on|desktop&#8221; button_two_custom_padding=&#8221;||||false|false&#8221; background_layout=&#8221;light&#8221; width=&#8221;50%&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;100%&#8221; width_last_edited=&#8221;on|phone&#8221; animation_style=&#8221;fade&#8221; animation_duration=&#8221;500ms&#8221; animation_delay=&#8221;300ms&#8221; title_font_tablet=&#8221;&#8221; title_font_phone=&#8221;&#8221; title_font_last_edited=&#8221;on|phone&#8221; content_font_tablet=&#8221;&#8221; content_font_phone=&#8221;&#8221; content_font_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;rgba(0,0,0,0)&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; width=&#8221;90%&#8221; max_width=&#8221;2560px&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#f7941e&#8221; header_font_size=&#8221;25px&#8221; header_line_height=&#8221;1.2em&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#f7941e&#8221; header_2_font_size=&#8221;25px&#8221; header_2_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>Statutory Communications<\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#f7941e&#8221; header_font_size=&#8221;25px&#8221; header_line_height=&#8221;1.2em&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#f7941e&#8221; header_2_font_size=&#8221;25px&#8221; header_2_line_height=&#8221;1.2em&#8221; custom_margin=&#8221;||12px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<div class=\"sub_stat_input\">\r\n\t<label for=\"\">Search: <\/label><input type=\"text\" class=\"input-medium search-query\" id=\"sub_cmpy_filter\" placeholder=\"\">\r\n<\/div>[\/et_pb_text][et_pb_tabs _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; body_text_color=&#8221;#000000&#8243; body_line_height=&#8221;1.8em&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_tab title=&#8221;2026&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/05\/Scrutinizer-Report-of-Postal-Ballot-E-voting-April-2026.pdf\">Scrutinizer Report of Postal Ballot E-voting April 2026<br \/>\n <\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/05\/IntimationSE20260505OrganonAcquisitionTranscript_Signed.pdf\">Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon &#038; Co.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/IntimationSE20260427_Organon_Acquisition_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of investor call recording in relation to the acquisition of Organon &#038; Co<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/FY26-27April-2026-Investor-Call-Recording-Acquisition-of-Organon-Co.mp3\">Audio Recording Link for the investor call in relation to the acquisition of Organon &#038; Co.<br \/>\n<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/Scrutinizer-Report_1_Postal-Ballot_2026.pdf\">Scrutinizer Report of Postal Ballot\/E-voting March 2026<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/Sun-Pharma-Notice-of-Postal-Ballot-and-Evoting-07042026.pdf\">Notice of Postal Ballot \/ E-voting (April 2026)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/03\/Sun-Pharma-Notice-of-Postal-Ballot-Mar-2026.pdf\">Notice of Postal Ballot \/ E-voting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/03\/SEIntimationSSSurveyonRTAServices.pdf\">Shareholder Satisfaction Survey on RTA Services<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/02\/IntimationSE20260203_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/02\/SEIntimationforSR.pdf\"> Sustainability Report F.Y. 2024-25<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/01\/IntimationSE20260131_Q3FY26_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q3FY26 Earnings Call Audio Recording<\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2025&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251110_for_Analyst_and_Investor_meeting_signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251107_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251105_Q2FY26_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q2FY26 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/Website-upload-RPT-for-HY-30-September-2025.pdf\">Related Party Transactions for the half year ended 30 September 2025<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/10\/seintimationforesg.pdf\">ESG Overview for FY2024-25<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/09\/IntimationSE20250918_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/09\/IntimationSE20250908_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250825_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250812_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/video\/CDSL_Sun%20Pharmaceutical%20Industries%20Limited_31072025%201.mp4\">Webcast Recording of 33rd Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250805_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/ScrutinizersReportSD.pdf\">Intimation of Scrutinizers Report for 33rd Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/07\/IntimationSE20250731_Q1FY26_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q1FY26 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/06\/IntimationSE20250625_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/RPT-Disclosure-for-Website-Upload-as-on-31-March-2025-1.pdf\"><span>Related Party Transactions for the half year ended 31 March 2025<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/IntimationSE20250522_Q4FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q4FY25 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/IntimationSE20250520_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/03\/Scrutinizer-Report_Postal-Ballot_Sun-Pharmaceutical-Industries-Limited_25-March-2025_signed.pdf\"><span>Scrutinizer Report for Postal Ballot\/E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/Sun-Pharma-Notice-of-Postal-Ballot-and-Evoting.pdf\"><span>Notice of Postal Ballot\/E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250207_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250204_for_Analyst_and_Investor_meeting1_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250204_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/Sun-Pharma-Sustanability-Report-FY-2023-24.pdf\"><span>Sustainability Report F.Y. 2023-24<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/01\/IntimationSE20250131_Q3FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q3FY25 Earnings Call Audio Recording<\/span><\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2024&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241203_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241111_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241107_for_Analyst_and_Investor_meeting_Singed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/10\/Related-Party-Transactions-for-the-half-year-ended-September-30-2024.pdf\"><span>Related Party Transactions for the half year ended September 30, 2024<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/10\/IntimationSE20241028_Q2FY25_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q2FY25 Earnings Call Audio Recording<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/09\/IntimationSE20240916_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240828_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/SEIntimationforESGOverview.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation regarding ESG Overview for the financial year 2023-24<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240813_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240807_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/cdsl-sun-pharmaceutical-industries-limited.mp4\"><span>Webcast Recording of 32<sup style=\"bottom: 0.5em;\">nd<\/sup>\u00a0Annual General Meeting of the Company<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240801_Q1FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q1FY25 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/Information-shared-with-BSE.pdf\"><span>Information shared with BSE for Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><span><u><\/u><u><\/u><\/span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/Information-shared-with-NSE.pdf\"><span>Information shared with NSE for Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/BSE_Observation-letter-for-Scheme-of-Arrangement_24.06.2024.pdf\">BSE Observation Letter for <span>Composite\u00a0<\/span>Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/NSE_Observation-letter-for-Scheme-of-Arrangement_24.06.2024.pdf\">NSE Observation Letter for <span>Composite\u00a0<\/span>Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/06\/TDS-Annexure-FY23-24.pdf\">Tax on Dividend for Final Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/06\/IntimationSE20240611_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240529_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240527_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/RPT-for-Website-March-2024.pdf\">Related Party Transactions for the half year ended March 31, 2024<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240522_Q4FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q4FY24 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/Scrutinizer-Report_Postal-Ballot_Sun-Pharmaceutical-Industries-Limited.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scrutiniser Report on Postal Ballot<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/Voting-Results.Website-upload.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"E-voting Results of Postal Ballot\"><span>E-voting Results of Postal Ballot<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/04\/Sun-Pharma-Notice-of-Postal-Ballot-E-voting..pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Notice of Postal Ballot &amp; E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/03\/IntimationSE20240305_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/SEIntimationforsurvey.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Shareholder Satisfaction Survey<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/IntimationSE20240212_SunPharma_SandP_Sustainability_Yearbook_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sun Pharma included in S&amp;P Global Sustainability Yearbook 2024<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/IntimationSE20240205_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/01\/IntimationSE20240131_Q3FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Disclosure of Q3FY24 Earnings Call Audio Recording<\/span><\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2023&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/03\/composite_scheme_of_arrangement.zip\"><span>Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/Related-Party-Transaction-Report-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Related Party Transactions for the half year ended September 30, 2023<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/IntimationSE_20231101_Q2FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/10\/IntimationSigned-29.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Board Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/09\/IntimationSE20230918_for_Analyst_and_Investor_Meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Sun_Pharma_ESG-Overview_FY2022-23_Final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ESG Overview FY2022-23<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/CDSL_Sun_Pharma_28082023.mp4\" target=\"_blank\" rel=\"noopener noreferrer\">Webcast Recording of 31st Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Intimation-of-Schedule-of-Analyst-or-Institutional-Investor-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Intimation-of-schedule-of-analyst-or-institutional-investor-meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/IntimationSE20230804_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/Related-Party-Transaction-Report-2.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Related Party Transactions for the half year ended March 31, 2023<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/IntimationSE20230803_Q1FY24_Investor_Call_Recording.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/07\/Annexure-for-Dividend-Tax.pdf\"><span>Tax on Dividend for Final Dividend<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/06\/Dividend-Waiver-Form.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Dividend Waiver Form<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/IntimationSE20230530AnalystMeetIntimationSinged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/1AdditionalLetterSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update relating to earnings call<\/a><u><\/u><u><\/u><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/2SEIntimationSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel<\/a><u><\/u><u><\/u><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/3OutcomeDirectorsSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Appointment of Director<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/4IntinationSE20230527MeetingSchedule.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/IntimationSE20230526_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/04\/Intimation_Update-on-Maholi-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on US FDA Inspection at Mohali Facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/Intimationsigned-16.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on IT Security Incident<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSE20230314_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSE20230303_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSigned-10.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of IT Security Incident<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/Dividend-Waiver-Form_Interim-Dividend_2022-23.pdf\" target=\"_blank\" rel=\"noopener\">Interim Dividend Waiver Form for the financial year 2022-23<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/IntimationSE20230203_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2022&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/IntimationSE20230131_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/01\/IntimationSigned-7.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of postal ballot and disclosure of voting results- Appointment of Mr. Sanjay Asher as an Independent Director<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/01\/Sun-Pharma-Sustainability-Report-2021-22-NE.pdf\" target=\"_blank\" rel=\"noopener\">Sustainability Report 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/12\/Notice-of-Postal-Ballot-Form.pdf\" target=\"_blank\" rel=\"noopener\">Notice of Postal Ballot for Appointment of Mr. Sanjay Asher &amp; Postal Ballot Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/Related-Party-Transactions-for-half-year-ended-30.09.2022.pdf\" target=\"_blank\" rel=\"noopener\">Related Party Transactions for half year ended 30.09.2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/IntimationSE20221108_for_Analyst_and_Investor_meetingsigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/IntimationSE20221101_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/09\/IntimationSE20220917_for_Analyst_and_Investor_meetingsigned-1.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/AGM_CDSL_Sun_Pharma_29082022.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording of 30th AGM<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSignedFinal.pdf\" target=\"_blank\" rel=\"noopener\">Voting Results and Scrutinizer\u2019s Report of 30th AGM<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Sun-Pharma-ESG-Overview-FY21-22.pdf\" target=\"_blank\" rel=\"noopener\">ESG Overview 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSE20220811_for_Analyst_and_Investor_meetingSigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationFinalSigned.pdf\" target=\"_blank\" rel=\"noopener\">Publication for 30th AGM and Evoting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSigned-2.pdf\" target=\"_blank\" rel=\"noopener\">Publication of 30th Annual General Meeting to be held by VC<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Form-for-waiver-forgoing-right-to-receice-Final-Dividend-for-financial-year-2021-22.pdf\" target=\"_blank\" rel=\"noopener\">Form for waiver-forgoing right to receive Final Dividend for financial year 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Retirement-of-Chairman.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 Retirement of Chairman<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/SPIL-Q1-2022-23.pdf\" target=\"_blank\" rel=\"noopener\">Publication of unaudited financial results for Q1<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSigned-1.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of the 30th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/IntimationSE20220729_Disclosure_Audio-_Call-_Q1FY23_signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/Self-Declaration-for-Non-resident-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Self-declaration for Non-resident Shareholder<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/Outcome-of-BM-29072022.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 July 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/SPIL-SE-Intimation-of-BM_July_2022_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Board Meeting July 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Closure-of-Trading-Window-Q1-2022-23.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Closure of Trading Window Q1 (2022-23)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Related_Party_Disclosure_under_Reg_23_for_March_2022_signed_Final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Consolidated Related Party Transactions for half year ended 31.03.2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/IntimationSE20220602_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/IntimationSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> Intimation under Regulation 30 \u2013 31 May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSE20220530_Disclosure_Earnings_Call_Audio.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Outcome30may2022.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation under Regulation 30 \u2013 30 May 2022 (Approval of Scheme of Amalgamation)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Director.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation under Regulation 30 \u2013 30 May 2022 (Appointment of Lead Independent Director\/ Re-appointment of Directors)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/SPILASCR202122.pdf\" target=\"_blank\" rel=\"noopener\">Annual Secretarial Compliance Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSE20220524_for_Analyst_and_Investor_meeting_24_May_22_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/BMIntimation.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of Board Meeting May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSigned.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 10th May, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/2-29th-March-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 29th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/SPIL-Intimation-under-Reg-30-March-21-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 March 21, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/4-8th-March-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 8th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/IntimationtoSEunderReg30dt22022022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 February 22, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/6-1st-February-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 1st February, 2022<br \/><\/a>\u00a0<br \/><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Press-Release-Phase-3-Data-for-WINLEVI-presents-at-the-AAD-Annual-Meeting.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 25th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Reg-30-Intimation-MoU-US-Ranbaxy-Litigation-23032022-Signed.pdf\" target=\"_blank\" rel=\"noopener\">Disclosure under Regulation 30 of SEBI Listing Regulations &#8211; Signing of Binding Memorandum of Understanding as to Material Terms of Settlement with the Direct Purchaser and End-Payor Plaintiffs in the In re Ranbaxy Generic Drug Application Antitrust Litigation in the U.S. District Court for the District of Massachusetts (USA)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Closure-of-trading-window.pdf\" target=\"_blank\" rel=\"noopener\">Closure of Trading Window<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/IntimationSE20220302_for_Analyst_and_Investor_meeting_08_Mar_22.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/02\/IntimationSE20220214_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/02\/IntimationSE20220205_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Interim-Dividend-Waiver-Form_2021-22.pdf\" target=\"_blank\" rel=\"noopener\">Interim Dividend Waiver Form_2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Outcome-of-Board-Meeting-held-on-31.01.2022.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on Jan 31, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Press-Release-Sun-Pharma-launches-CEQUA-in-Canada.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 27th January, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Intimationfinal.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting January 2022<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2021&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/12\/Press-Release-Sun-Pharma-receives-DCGI-approval-for-Molxvir-Molnupiravir-in-India.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 28th December, 2021<br \/> <\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/9-15th-December-2021.pdf\" target=\"_blank\" rel=\"noopener\"><\/a><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/9-15th-December-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 15th December, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/12\/consolidated-Half-year-ended-sept-21-RPT-Final-for-SE.pdf\" target=\"_blank\" rel=\"noopener\">Consolidated Related Party Transactions for half year ended 30.09.2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/10-30th-November-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 30th November, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211122_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211112_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Press-Release-Sun-Pharma-gearing-up-to-introduce-molnupiravir-under-the-brand-name-Molxvir\u00ae-in-India.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 11th November, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211109_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Intimation-to-Stock-Exchanges-reg-GxMDL-antitrust-litigation-Final-5-11-....pdf\" target=\"_blank\" rel=\"noopener\">Signing of settlement agreements with the Direct Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania (USA) by our 2 subsidiary companies.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Outcome-of-Board-Meeting-held-on-Nov-02-2021.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on Nov 02, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/10\/ClosureofTradingwindow.pdf\" target=\"_blank\" rel=\"noopener\">Closure of trading window<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210928_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210917_for_Analyst_and_Investor_meetingSigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Webcast-of-29th-AGM.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording of 29th Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Press-Release-Sun-Pharma-launches-Chericof-12.pdf\">Intimation under Regulation 30- 28th September, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Intimation-to-exchange-Sanction-of-Scheme-of-Amalgamation-and-Merger-of-Sun-Pharma-Global-FZE-with-SPIL.pdf\" target=\"_blank\" rel=\"noopener\">Intimation to exchange Sanction of Scheme of Amalgamation and Merger of Sun Pharma Global FZE with SPIL<\/a><\/p>\n<p><a href=\"&lt;a href=\">Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210907signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Reg30resignation.pdf\" target=\"_blank\" rel=\"noopener\">Resignation of Mr. Vivek Channd Sehgal<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/12-1st-September-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 1st September, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/29thAGMVotingResults.pdf\" target=\"_blank\" rel=\"noopener\">Voting Results of 29th AGM and Scrutiniser\u2019s Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/CombinedOutcomeof29thAGMupload.pdf\" target=\"_blank\" rel=\"noopener\">Proceedings of 29th AGM and Intimation of Changes in Directors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Chairman-Speech-at-the-29th-Annual-General-Meeting-held-on-31-August-2021.pdf\" target=\"_blank\" rel=\"noopener\">Chairman Speech at the 29th Annual General Meeting held on 31 August 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Reg47NewspaperAdvtwithCoverletter.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice of 28th Annual General Meeting and E-voting \u2013 Post-dispatch<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Form-for-waiver-forgoing-right-to-receice-Final-Dividend-for-financial-year-2020-21.pdf\" target=\"_blank\" rel=\"noopener\">Form for waiver-forgoing right to receive Final Dividend for financial year 2020-21<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/SPILReg47NewspaperIntPredispatch05082021.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure \u2013 Pre-dispatch<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/SPILAGMBookClosureIntimation04082021.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of AGM and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/OutcomeBMJuly302021.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on July 30, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/07\/Newspaper-Advertisement-for-Notice-for-transfer-of-equity-shares-and-unclaimed-Dividend-to-IEPF.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/07\/IntimationofBMQ1202122.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting July 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/04\/ASCR.pdf\" target=\"_blank\" rel=\"noopener\">Annual Secretarial Compliance Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Consolidated-Related-Party-Transactions-for-half-year-ended-31.03.2021.pdf\" target=\"_blank\" rel=\"noopener\">Consolidated Related Party Transactions for half year ended 31.03.2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/06\/225_IntimationSE20210607.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimationSUNAZ28052021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of Acquisition of trademarks and patent license for Dapagliflozin and its combinations from AstraZeneca AB<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/Stock-Exchange-Letter-Intimation-Schedule-of-Analyst-Fund-Meet.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/Outcome27052021Final.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of the Board Meeting \u2013 May 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimation20052021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation for Appointment of Additional Independent Directors on the Board of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/IntimationofBMQ410052021.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting May 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/usa\/wp-content\/uploads\/sites\/2\/2021\/05\/IntimationtoStockExchange30042021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/usa\/wp-content\/uploads\/sites\/2\/2021\/05\/ReplytoStockExchangeMSDforMolnupiravir29042021Final.pdf\" target=\"_blank\" rel=\"noopener\">Clarification to Stock Exchanges on News Item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/04\/IntimationtoStockExchange06042021PharmarackUpdate.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/cdsl_sunpharma-share-holder.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording for Tribunal Called Meeting of Equity Shareholders of the Company held on March 16, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/04\/IntimationtoStockExchange31032021AWACS.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/IntimationtoStockExchange25032021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/VotingResultsandScrutinizerReport18032021.pdf\">Voting Results of the NCLT Convened Meeting of Equity Shareholders held on March 16, 2021 and Scrutinizer\u2019s Reports<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/ProceedingsofNCLTconvenedmeetings16032021.pdf\">Proceedings of the NCLT Convened Meetings of Unsecured Creditors and Equity Shareholders held on March 16, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/SPILStockExchangeIntimationWRSBioproductsUpdate10032021.pdf\">Update on Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/SPILStockExchangeIntimationWRSBioproducts05032021.pdf\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationtoSEforNewspaperAdvtofNCLTMeetingsCAA.pdf\">Newspaper Advertisement for NCLT Meetings of Equity Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationofSettlementOrdertoExchanges11022021-1.pdf\">Intimation Letter for Conclusion of settlement proceedings with SEBI<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Notice-of-NCLT-Convened-Meeting-of-Unsecured-Creditors-1.pdf\">Notice of NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Notice-of-NCLT-Convened-Meeting-of-Equity-Shareholders-1.pdf\">Notice of NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/NewspaperAdvertisementsubmission-30121-1.pdf\">Newspaper Advertisement for Intimation of Record Date for Payment of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_15G-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 15G<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Interim-Dividend-Waiver-Form_2020-21-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Interim Dividend Waiver Form_2020-21<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_15H-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 15H<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/OutcomeofBoardMeeting290121-1.pdf\">Outcome of the Board Meeting \u2013 January 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_10F-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 10F<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/StockExchangeIntimationInterimDividend202021-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation to Stock Exchange for considering Declaration of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationofBoardMeetingQ3202021-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting January 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimationSUNAZ28052021.pdf\" rel=\"attachment wp-att-9913\">StockExchangeIntimationSUNAZ28052021<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2020&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Webcast-Recording-of-28th-Annual-General-Meeting-of-the-Company-for-the-year-2019-20.docx\">Webcast Recording of 28th Annual General Meeting of the Company for the year 2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeofBoardMeetingQ2Nov032020Final.pdf\">Outcome of Board Meeting \u2013 November 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofBoardMeetingQ22020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting November 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/sam.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scheme of Amalgamation and Merger<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-CTC-BM-July-2020-for-SPGFZE-Merger-signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Board Resolution approving Scheme of Amalgamation and Merger<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/RPTDisclosure30092020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Related Party Disclosure on consolidated basis for the half year ended September 30, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Post-Buy-Back-Public-Announcement-September-26-2020.pdf\">Post Buy-Back Public Announcement \u2013 September 26, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofclosureofBuyback25092020.pdf\">Intimation of Closure of Buy Back \u2013 September 25, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Secretarial-Audit-Report-of-Material-Subsidiaries_2019-20.pdf\">Secretarial Audit Report of Material Subsidiaries_2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/VotingResults28thAGM.pdf\">Voting Results for the 28th Annual General Meeting and Scrutinizer\u2019s Consolidated Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-28th-Annual-General-Meeting.pdf\">Outcome of 28th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/28th-AGM-Speech.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman Speech at the 28th Annual General Meeting held on 27 August 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/CoveringletterforNewspaperSubmissionFinal.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY2019-20-1.pdf\">BUSINESS RESPONSIBILITY REPORT -FY2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Self-Declaration-Format-for-Non-Resident-Shareholders.pdf\">Self Declaration Format for Non-Resident Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-the-28th-Annual-General-Meeting.pdf\">Notice of the 28th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-AR-2019-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL ANNUAL REPORT -FY2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEME-Disclosure-under-SEBI-Share-Based-Employee-BenefitsRegulations2014-as-on-Mar-312020.pdf\">EMPLOYEES\u2019 STOCK OPTION SCHEME-Disclosure under SEBI (Share Based Employee Benefits)Regulations2014 as on Mar 312020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Upadate-on-Intimation-under-Regulation-30-of-Listing-Regulations.pdf\">Update on Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Final-Dividend-for-financial-year-2019-2020_Final.pdf\">Form for waiver-forgoing right to receive Final Dividend for financial year 2019-2020_Final<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-under-Regulation-30-of-Listing-Regulations.pdf\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome31072020.pdf\">Outcome of the Board Meeting &#8211; July 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofnewspaperpublicationforIEPF.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SEIntimationofBM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting July 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/RPTDisclosureIntimationtoSE.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Related Party Disclosure on consolidated basis for the half year ended March 31, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Financials27052020FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 May 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofBoardMeeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting May 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Update-on-Halol-facility.pdf\">Stock Exchange Letter Update on Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Additional-details-for-OAI-classification-for-Halol-facility.pdf\">Additional details for OAI classification for Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Corrigendum-to-Public-Announcement-for-Buy-Back-of-Equity-Shares-March-24-2020.pdf\">Corrigendum to Public Announcement for Buy-Back of Equity Shares &#8211; March 24, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Public-Announcement-for-Buy-Back-of-Equity-Shares-\u2013-March-18-2020.pdf\">Public Announcement for Buy-Back of Equity Shares \u2013 March 18, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-the-Board-Meeting-March-2020-Approval-of-Buy-Back.pdf\">Outcome of the Board Meeting March 2020 &#8211; Approval of Buy-Back<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stockexchangeintimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting March 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/StockExchangeIntimation06022020ID-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Intimation of Record Date for payment of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome06022020.pdf\">Outcome of the Board Meeting \u2013 February 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Interim-Dividend-Waiver-Form_2019-20.pdf\">Interim Dividend Waiver Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILpriorIntimationtoStkExchangesforInterimDividend03022020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation to Stock Exchange for considering Declaration of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Intimation-of-Board-Meeting-February-2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting February 2020<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2019&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationToStockExchange.pdf\">Intimation to Stock Exchange for NCLT Order on Composite Scheme of Arrangement<\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationToStockExchange.pdf\">Update on US FDA Halol Inspection<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Antitrust-Litigation-in-US.pdf\">Stock Exchange Letter Antitrust Litigation in US<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-November-2019.pdf\">Outcome of Board Meeting &#8211; November 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationofBoardMeeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting November 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Related-Party-Disclosure-on-consodilated-basis-for-half-year-ended-September-30-2019.pdf\">Related Party Disclosure on consodilated basis for half year ended September 30, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/27thAGMSpeech.pdf\">Chairman Speech at the 27th Annual General Meeting held on August 28, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-August-2019.pdf\">Outcome of Board Meeting &#8211; August 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationofBoardMeeting-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification\/Confirmation on News Item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/LettertoSESPILNewspaperadvt.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice of 27th Annual General Meeting, E-voting and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILSEIntimationofBMAugust2019.pdf\">SPIL Intimation of Board Meeting August 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationBookClosureAGM.pdf\">SPIL Intimation of AGM date and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEMES-Disclosure-under-SEBI-Share-Based-Employee-Benefits-Regulations-2014-as-on-March-31-2019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">EMPLOYEES\u2019 STOCK OPTION SCHEMES &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Business-Responsibility-Report-FY2018-19.pdf\">Business Responsibility Report FY2018-19<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Dividend-Waiver-Form_2018-19.pdf\">Dividend Waiver Form 2018-19<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Voting-Results-alongwith-Scrutinizers-Report-of-TCM-held-on-June-04-2019.pdf\">Voting Results alongwith Scrutinizer\u2019s Report of TCM held on June 04, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Proceedings-of-the-NCLT-Convened-Meeting-of-Shareholders-and-Unsecured-Creditors-2019.pdf\">Proceedings of the NCLT Convened Meeting of Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-clarification-on-news-item-2019.pdf\">Stock Exchange clarification on news item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ScrutinizerReportVotingResults.pdf\">Scrutinizer Report SPIL NCLT Meeting 04 06 2019 Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Advertisement-for-Notice-for-transfer-of-equity-shares-and-unclaimed-dividend-to-IEPF-2019.pdf\">Advertisement for Notice for transfer of equity shares and unclaimed dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Notice-of-Tribunal-Convened-Meeting_Unsecured-Creditors_June-04-2019.pdf\">Notice of Tribunal Convened Meeting Unsecured Creditors June 04, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Outcome-of-the-Board-Meeting-May-28-2019.pdf\">Outcome of the Board Meeting &#8211; May 28, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/SPIL-Intimation-of-BM-May-2019.pdf\">SPIL Intimation of BM May 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-information-of-Advertisement-2019.pdf\">Stock Exchange Intimationm Of Advertisement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-\u2013-Attendance-Slip-for-NCLT-Convened-Meeting-for-Equity-Shareholders-2019-1.pdf\">Sun Pharma \u2013 Attendance Slip for NCLT Convened Meeting for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-\u2013-Notice-of-NCLT-Convened-Meeting-including-Proxy-Form-and-Attendance-Slip-for-Equity-Shareholders-2019-1.pdf\">Sun Pharma &#8211; Notice of NCLT Convened Meeting including Proxy Form and Attendance Slip for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-\u2013-Proxy-Form-for-NCLT-Convened-Meeting-for-Equity-Shareholders.pdf\">Sun Pharma \u2013 Proxy Form for NCLT Convened Meeting for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Related-Party-Disclosure-on-consodilated-basis-for-half-year-ended-September-30-2019-1.pdf\">Related Party Disclosure on consolidated basis for half year ended 31st March, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-the-Board-Meeting-February-12-2019.pdf\">Notice of Board Meeting &#8211; February 12, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-the-Board-Meeting-February-12-2019-2.pdf\">Outcome of the Board Meeting &#8211; February 12, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Observation-Letter-BSE.pdf\">Observation Letter \u2013 BSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Observation-Letter-NSE.pdf\">Observation Letter \u2013 NSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Sun-Pharma-Investor-Update.pdf\">Stock Exchange Letter Sun Pharma Investor Update<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-Letter-to-SEBI-on-alleged-second-whistleblower-complaint-filed-against-Sun.pdf\">Stock Exchange Letter to SEBI on alleged second whistleblower complaint filed against Sun<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-update-on-commercialsed-XELPROS-in-US.pdf\">Stock Exchange Letter update on commercialsed XELPROS in US<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Completion-of-transaction-Pola-Pharma-Japan.pdf\">Stock Exchange Letter Completion of transaction Pola Pharma, Japan<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2018&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Clarification-on-Recent-Media-Reports.pdf\">Stock Exchange Letter Clarification on Recent Media Reports<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-under-Regulation-30-of-the-SEBI-Listing-Obligations-and-Disclosure-Requirements-Regulations-2015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Intimation-of-settlement-in-re-Modafinil-Antitrust-Litigation-in-US-with-certain-plaintiffs.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Intimation of settlement in re Modafinil Antitrust Litigation in US with certain plaintiffs<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-meeting-\u2013-Nov-13-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board meeting &#8211; Nov 13, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-meeting-\u2013-Nov-13-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board meeting &#8211; Nov 13, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-regarding-inter-se-change-in-shareholding-of-promoter-group-pursuant-to-Scheme-of-Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation regarding inter-se change in shareholding of promoter group pursuant to Scheme of Amalgamation.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-National-Stock-Exchange-of-India-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-BSE-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Shareholding-Patter-\u2013-September-30-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Shareholding Pattern &#8211; September 30, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Investor-\u2013-Shareholder-Information-\u2013-Statutory-Communications-\u2013-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Investor &#8211; Shareholder Information &#8211; Statutory Communications \u2013 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Results-of-26th-Annual-General-Meeting-to-Stock-Exchanges-along-with-Scrutinizers-Report.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Voting Results of 26th Annual General Meeting to Stock Exchanges along with Scrutinizers Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Composite-Scheme-of-Arrangement-1.pdf\">Composite Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Chairman-speech-at-26th-Annual-General-Meeting-held-on-September-26-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman speech at 26th Annual General Meeting held on September 26, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-26th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Proceedings of 26th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-Mohali-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification to Stock Exchanges on Mohali facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-news-regarding-Halol-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification to Stock Exchanges on news regarding Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement.pdf\">Newspaper Advertisement &#8211; Notice of 26th AGM, E-voting and Book Closure &#8211; English and Gujarati<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY2017-18.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report FY2017-18<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receice-Dividend-for-financial-year-ended-31032018.pdf\">Form for waiver-forgoing right to receive Dividend for financial year ended March 31, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEMES-\u2013-Disclosure-under-SEBI-Share-Based-Employee-Benefits-Regulations-2014-as-on-March-31-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">EMPLOYEES\u2019 STOCK OPTION SCHEMES &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-26th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of 26th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-of-Book-closure-and-AGM-date.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Book closure and AGM date<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeBM14082018.pdf\">Outcome of Board Meeting &#8211; August 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-\u2013-August-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting &#8211; August 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-news-regarding-Halol-facility-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification on news regarding Halol<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/VotingResultNCLTmeeting01062018-1.pdf\">Voting Results of NCLT Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-NCLT-Meetings-1.pdf\">Proceedings of National Company Law Tribunal Meetings held on June 01, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcomeallotmentcomm24052018.pdf\">Outcome of Board Meeting May 25, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeBoardMeetingMay_25_2018.pdf\">Notice of Board Meeting &#8211; May 25, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/AllotmentofEquityshares.pdf\">Allotment of Equity Shares under SUN ESOS 2015 &#8211; May 24, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-ad-Notice-for-NCLT-Convened-Meeting-of-Equity-Shareholders-Unsecured-Creditors-and-Notice-for-Remote-E-Voting-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice for NCLT Convened Meeting of Equity Shareholders &amp; Unsecured Creditors and Notice for Remote E-Voting for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Shareholding-Pattern-2018.pdf\">Shareholding Pattern<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\">SPIL &#8211; Attendance Slip for NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Unsecured-Creditors.pdf\">SPIL &#8211; NCLT Convened Meeting Notices of Unsecured Creditors along with Proxy Form and Attendance Slip<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Equity-Shareholders-1.pdf\">SPIL &#8211; Attendance Slip for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-NCLT-Convened-Meeting-Notices-of-Equity-shareholders-along-with-Proxy-Form.pdf\">SPIL &#8211; NCLT Convened Meeting Notices of Equity shareholders along with Proxy Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationtostockexchangesMar102018.pdf\">Intimation to stock exchanges Mar 10 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Update-on-USFDA-Halol-Inspection.pdf\">Update on USFDA Halol Inspection<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-to-Stock-Exchanges-under-Regulation-30-\u2013-Updates.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure to Stock Exchanges under Regulation 30 \u2013 Updates<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allotment-of-Equity-Shares-under-SUN-ESOS-2015-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Allotment of Equity Shares under SUN ESOS 2015 &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-BSE-on-News-Clarification-Ankleshwar-unit-Feb-5-2018.pdf\">SPIL Reply to BSE on News Clarification Ankleshwar unit Feb 5 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-NSE-on-News-Clarification-Ankleshwar-unit-Feb-5-2018.pdf\">SPIL Reply to NSE on News Clarification Ankleshwar unit Feb 5, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-to-Stock-Exchanges-under-Regulation-30-\u2013-Updates-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure to Stock Exchanges under Regulation 30 \u2013 Updates<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2017&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-Regulations-2015.pdf\">Scheme of Arrangement &#8211; Compliance of Regulation 37 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/disclosure-to-stock-exchange-under-regulation.pdf\">Disclosure to Stock Exchanges under Regulation 30<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcome-of-board-meeting_14-november-2017.pdf\">Outcome of Board Meeting 14 November 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcomeof-allottment-commitee-meeting_14-november-2017.pdf\">Outcome of Allotment Committee Meeting 14 November 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-November-14-2017.pdf\">Notice of Board Meeting &#8211; November 14 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcome-of-allotment-commitee-sept26-2017.pdf\">Outcome of Allottment Commitee Meeting September 26 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-US-FDA-Dadra-Inspection.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on US FDA Dadra Inspection<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/votingresultsfor25thagm.pdf\">Voting Results for the 25th AGM and Scrutinizers Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Chairman-and-Managing-Director-Speech-at-25th-Annual-General-Meeting-held-on-September-26-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman and Managing Director Speech at 25th Annual General Meeting held on September 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-25th-AGM.pdf\">Proceedings of 25th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-English-Ahmedabad-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure English Ahmedabad Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-English-Mumbai-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure English Mumbai Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-Gujarati-Ahmedabad-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure Gujarati Ahmedabad Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-of-right-to-receive-Dividend-for-the-financial-year-ended-March-31-2017.pdf\">Form for waiver-forgoing of right to receive Dividend for the financial year ended March 31 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2016-17.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ESOS-Disclosure-under-SEBI-SBEB-Regulations-2014-as-on-March-31-2017.pdf\">ESOS &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-25th-AGM-2016-17.pdf\">SPIL Notice of 25th AGM 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL_Attendance_Slip_ProxyForm-_2016-17.pdf\">SPIL Attendance Slip and Proxy Form 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Outcome-of-Allottment-Commitee-Meeting_August-11-2017-1.pdf\">Outcome of Allottment Commitee Meeting August 11, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting_August-11-2017-1.pdf\">Outcome of Board Meeting August 11, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting_August-11-2017.pdf\">Notice of Board Meeting August 11 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-of-change-in-key-managerial-person-for-determining-materiality-of-an-event-or-information.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of change in key managerial person for determining materiality of an event or information<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-NCLT-Convened-Meetings-held-on-June-20-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Proceedings of NCLT Convened Meetings held on June 20, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scrutinizers-Report-for-the-NCLT-Convened-Meeting-of-Unsecured-Creditors.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scrutinizer&#8217;s Report for the NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Consolidated-Scrutinizers-Report-for-the-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Consolidated Scrutinizer&#8217;s Report for the NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Results-of-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Voting Results of NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Correction-Letter-to-the-Letter-to-Stock-Exchange-for-outcome-of-Board-Meeting-May-26-2017.pdf\">Correction Letter to the Letter to Stock Exchange for outcome of Board Meeting May 26 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting_May-26-2017.pdf\">Outcome of Board Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Allottment-Commitee-Meeting_May-26-2017.pdf\">Outcome of Allottment Commitee Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-regarding-Notice-for-Postal-Ballot-and-Remote-E-voting-for-the-National-Company-Law-Tribunal-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice for Postal Ballot and Remote E-voting for the National Company Law Tribunal Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-regarding-Notice-of-the-National-Company-Law-Tribunal-Convened-Meetings-of-Equity-Shareholders-and-Unsecured-Creditors.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice of the National Company Law Tribunal Convened Meetings of Equity Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting_May_26_2017.pdf\">Notice of Board Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-NCLT-Convened-Meeting-of-Equity-shareholders-Proxy-Attendance-Slip.pdf\">Notice of NCLT Convened Meeting of Equity Shareholders including Proxy Form and Attendance Slip<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Tribunal-Convened-Meeting-of-Unsecured-Creditors-of-the-Company.pdf\">Notice of Tribunal Convened Meeting of Unsecured Creditors of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Form for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Acquisition-of-Thallion-Pharmaceuticals-Inc..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Thallion Pharmaceuticals Inc.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/BSE-Observation-letter.pdf\">Observation letter \u2013 BSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NSE-observation-letter.pdf\">Observation letter \u2013 NSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-February-14-2-2017.pdf\">Outcome of Board Meeting February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allottment-Commitee-Meeting-Outcome-of-Meeting-February-14-2-2017.pdf\">Allottment Commitee Meeting Outcome of Meeting February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeofBoardMeeting14022017.pdf\">Notice of Board Meeting &#8211; February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ComplaintReportNSE.pdf\">Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-BSE-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement-for-Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2016&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-BSE-on-news-clarification-Ahmednagar-unit-Dec-29-2016-rev.pdf\">SPIL Reply to BSE on news clarification Ahmednagar unit Dec 29, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILReplytoNSEonnewsclarificationAhmednagarunitDec292016.pdf\">SPIL Reply to NSE on news clarification Ahmednagar unit Dec 29, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-under-Regulation-30-of-the-SEBI-Listing-Obligations-and-Disclosure-Requirements-Regulations-2015-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-Compliance-of-Regulation-37of-SEBI-Listing.pdf\">Scheme of Arrangement &#8211; Compliance of Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-acquisition-of-Ocular-Technologies-Sarl-\u2013-closure-of-transaction-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on acquisition of Ocular Technologies, Sarl \u2013 closure of transaction<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-\u2013-Reply.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter \u2013 Reply<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-\u2013-Update-on-USFDA-Inspection-for-Halol-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter &#8211; Update on USFDA Inspection for Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-to-acquire-Biosintez-in-Russia.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sun Pharma to acquire Biosintez in Russia<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allottment-Commitee-Meeting_Outcome-of-Meeting.pdf\">Allottment Commitee Meeting Outcome of Meeting<\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-Intimation-on-CFO-2016.pdf\">Stock Exchange Intimation on CFO<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-10th-November-2016.pdf\">Notice of Board Meeting &#8211; 10th November, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Change-in-Window-Closure-Date-for-trading-by-Designated-Persons.pdf\">Change in Window Closure Date for trading by Designated Persons<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Completion-of-Buyback-and-Submission-of-Post-Buyback-Public-Announcement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Completion of Buyback and Submission of Post Buyback Public Announcement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Submission-of-Corrigendum-to-the-Post-Buyback-Public-Announcement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Submission of Corrigendum to the Post Buyback Public Announcement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Receipt-of-approval-for-reclassification-of-shares-under-Regulation-31A7-of-the-SEBI-Listing-Obligation-Disclosure-Requirements-Regulations-2015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Receipt of approval for reclassification of shares under Regulation 31A(7) of the SEBI (Listing Obligation &amp; Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILSubmissionofAOA.pdf\">Submission of new set of Articles of Association of the Company<\/a><\/p>\n<p><span>September 22, 2016<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL24thAGMVOTINGRESULTS.pdf\">Voting Results of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILProceedingsAGM17092016.pdf\">Proceedings of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SCRUTINIZERS-REPORT.pdf\">Srcutinizer&#8217;s Report on Voting Results of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/24th-AGM-Speech-Sept-2016.pdf\">Chairman and Managing Director Speech at 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Buyback-LOF.pdf\">Letter of offer for Buyback<\/a><\/p>\n<p>September 14, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL_Draft-AOA-with-proposed-amendments.pdf\">Draft Articles of Association of SPIL<\/a><\/p>\n<p>August 27, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receice-Dividend-for-financial-year-ended-31032016-final.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-16<\/a><\/p>\n<p>August 18, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-24th-AGM-2016.pdf\">NOTICE OF 24th ANNUAL GENERAL MEETING<\/a><\/p>\n<p>August 17, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-BRR.pdf\">Business Responsibility Report 2015-16<\/a><\/p>\n<p>August 17, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/STOCKEXCHANGEINTIMATION.pdf\">Notice of Board meeting scheduled on August 12, 2016<\/a><\/p>\n<p>August 05, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/P.1-2-Draft-Letter-of-Offer-Sun-Pharmaceutical-Industries-Ltd-Buyback.pdf\">Draft letter of offer for Buyback &#8211; Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>July 08, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Public-Announcement-Sun-Pharmaceutical-Industries-Limited-Buyback-through-Tender-Offer-Route.pdf\">Public Announcement of Sun Pharmaceutical Industries Limited for buyback through Tender Offer<\/a><\/p>\n<p>June 28, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeJune232016.pdf\">Outcome of Board Meeting dated June 23, 2016<\/a><\/p>\n<p>June 23, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-BM-30.05.2016.pdf\">Outcome of the Board meeting held on 30th May, 2016<\/a><\/p>\n<p>May 30, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimationforreclassificationofpromoter23052016.pdf\">Intimation pertaining to Request letter(s) received from certain Promoter group under Regulation 31A of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p>May 23, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/BMINTIMATION30.05.2016.pdf\">Notice of Board meeting scheduled on 30th May, 2016<\/a><\/p>\n<p>May 13, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-intimation-of-withdrawal-of-credit-rating.pdf\">Intimation of withdrawal of CARE rating at Company\u2019s request<\/a><\/p>\n<p>April 07, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Announcement.pdf\">Termination of collaboration established in 2011 between affiliates of Merck Sharp &amp; Dohme and Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>February 15, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-BM-12.02.2016.pdf\">Outcome of the Board meeting held on 12th February, 2016<\/a><\/p>\n<p>February 12, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SEINTIMATIONBM31122015SPIL.pdf\">Notice of Board Meeting scheduled on 12th February 2016<\/a><\/p>\n<p>January 29, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Intimation-to-Stock-Exchanges_Jan-22-2016-regarding-CCI-approval-for-sale-of-CNS-division.pdf\">CCI approval for sale of CNS division to Strides<\/a><\/p>\n<p>January 22, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Disclosure-Regarding-Stock-Exchanges-Under-Regulation-30-Nov-22-2016.pdf\">Disclosure to Stock Exchanges under Regulation 30<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2015&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Authorized-KMP-to-determine-materiality-of-event-or-information.pdf\">Authorized KMPs for determining materiality of an event or information<\/a><\/p>\n<p>November 30, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-Wind-Energy-Project.pdf\">Update on Wind Energy Project<\/a><\/p>\n<p>November 24, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Result-of-Postal-Ballot-as-per-Clause-35A_06.11.2015.pdf\">Result of Postal Ballot as per Clause 35A of the Listing Agreement alongwith Scrutinizers Report<\/a><\/p>\n<p>November 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20151102-Report-on-Proceedings-of-23rd-AGM-with-Scrutinizer-report-_-voting-results.pdf\">Report on Proceedings of 23rd AGM with Scrutinizer report &amp; voting results<\/a><\/p>\n<p>November 02, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/23rd-AGM-Chairman-Speech-31Oct-2015.pdf\">23rd AGM Chairman Speech<\/a><\/p>\n<p>October 31, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Dividend-for-year-end-31-03-15.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-15<\/a><\/p>\n<p>October 20, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-23rd-AGM-2015.pdf\">Notice of 23rd Annual General Meeting<\/a><\/p>\n<p>October 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY14-15_0.pdf\">Business Responsibility Report 2014-15<\/a><\/p>\n<p>October 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeofPostalBallotForm.pdf\">Notice of Postal Ballot &amp; Postal Ballot form<\/a><\/p>\n<p>October 05, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Result-of-Court-Convened-Meeting-of-SPIL-to-consider-the-Scheme-of-Merger-of-SPGI-with-the-Company.pdf\">Voting Result of Court Convened Meeting of SPIL to consider the Scheme of Merger of SPGI with the Company<\/a><\/p>\n<p>June 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-for-Court-Convened-Meeting_SPIL_SPGI.pdf\">Notice for the Court convened meeting for approval of the Scheme of Merger of Sun Pharma Global Inc with Sun Pharmaceutical Industries Ltd.<\/a><\/p>\n<p>May 18, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Draft-Scheme-of-Amalgamation-_-other-documents.pdf\">Draft Scheme of Amalgamation and other documents pertaining to the proposed merger of Sun Pharma Global Inc. with the Company<\/a><\/p>\n<p>March 12, 2015<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2014&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ClarificationregardingCCIapproval.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification regarding CCI approval to the Scheme of Arrangement between Ranbaxy and Sun Pharma<\/a><\/p>\n<p>December 01, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Outcome-of-22nd-AGM-2014-Voting-Results-as-per-35AScrutinizer-Reports-1.pdf\">Outcome of 22nd AGM 2014, Voting Results as per 35A and Scrutinizer Reports<\/a><\/p>\n<p>October 01, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/22th-AGM-Chairman-Speech-Sep-2014_0-1.pdf\">22nd AGM Chairman Speech<\/a><\/p>\n<p>September 29, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-AGM-Notice-2013-14-1.pdf\">Notice of 22nd Annual General Meeting<\/a><\/p>\n<p>September 04, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-IV-2.pdf\">Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)<\/a><\/p>\n<p>September 04, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2013-14-1.pdf\">Business Responsibility Report 2013-14<\/a><\/p>\n<p>September 02, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-CCI-Communication-1.pdf\">Intimation pertaining to communication from the Competition Commission of India (CCI)<\/a><\/p>\n<p>August 27, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/CCM-Voting-Results-1.pdf\">Outcome of Court Convened Meeting &amp; Poll Results<\/a><\/p>\n<p>August 26, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Dividend-for-Y.E.31-03-14-1.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-14<\/a><\/p>\n<p>August 26, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Court-Convened-Meeting-on-22.08.2014-Scheme-ExplStmt-Attd-Slip-_-Proxy-Form-1.pdf\">Notice of Court Convened Meeting on 22.08.2014, Scheme, ExplStmt, Attd Slip &amp; Proxy Form<\/a><\/p>\n<p>July 29, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-between-Ranbaxy-_-Sun-Pharma-1.pdf\">Scheme of Arrangement between Ranbaxy Laboratories Limited And Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>May 12, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20140509-Proceedings-of-Court-convened-Meeting-of-Equity-Shareholders-held-on-May-05-2014-1.pdf\">Proceedings &amp; Results of Court convened Meeting of Equity Shareholders held on May 05, 2014<\/a><\/p>\n<p>May 09, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-arrangement-reconstruction-between-SunPharma-GlobalFZE-SunPharmaceuticalIndustriesLtd-1.pdf\">Scheme of arrangement &amp; reconstruction between Sun Pharma Global FZE &amp; Sun Pharmaceutical Industries Ltd.<\/a><\/p>\n<p>January 21, 2014<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2013&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/21-AGM-Chairman-Speech-Sep-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">21st AGM Chairman Speech<\/a><\/p>\n<p>October 01, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2012-13.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report 2012-13<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-Notice-of-Adjourned-Twentieth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Adjourned Twentieth Annual General Meeting<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130905-SPIL-Proxy-Form-_-Attendance-Slip..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip for Adjourned Twentieth AGM &amp; Twenty-first AGM<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130905-Notice-of-Twenty-first-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Twenty-first Annual General Meeting<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130904-Form-for-waiver-forgoing-right-to-receive-Dividend-for-Y.E.-31-03-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form for waiver forgoing right to receive Dividend year ended 31-03-2013<\/a><\/p>\n<p>September 04, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130805-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>August 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130718-Intimation-regarding-Record-Date-Stock-Exchanges_0.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Intimation of Record Date for Bonus Shares<\/a><\/p>\n<p>July 18, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130715-Postal-Ballot-Result-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Result of Postal Ballot<\/a><\/p>\n<p>July 15, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130703-Quarterly-compliance-report-of-the-Corp.-Gov.30-06-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corporate Governance 30-06-2013<\/a><\/p>\n<p>July 03, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-30.05.2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Form 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-30.05.2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Request for Bonus Equity Share in Electronic Form &amp; Envelopes<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Notice-30.05.2013-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Notice 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Intimation-10-06-13-Postal-Ballot.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Intimation of Postal Ballot 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130401-Quarterly-compliance-report-of-the-Corp.-Gov.31-03-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-03-2013<\/a><\/p>\n<p>April 01, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130123-Notice-of-Board-Meeting-for-quarter-end-31-12-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2012<\/a><\/p>\n<p>January 23, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130108-Notice-of-Convening-the-meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Convening the meeting of Equity Shareholders<\/a><\/p>\n<p>January 08, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130109-Quarterly-compliance-report-of-the-Corp.-Gov.31-12-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-12-2012<\/a><\/p>\n<p>January 07, 2013<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2012&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Code-of-Conduct-SPIL-as-on-31.03.2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Code of Conduct for Directors and Senior Management<\/a><\/p>\n<p>December 14, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121022-Notice-of-Board-Meeting-for-quarter-end-30-09-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2012<\/a><\/p>\n<p>October 22, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121012-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 12, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-Notice-of-Twentieth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Twentieth Annual General Meeting<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121011-Notice-for-20th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice for 20th Annual General Meeting<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-SPIL-Proxy-Form-_-Attendance-Slip.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121010-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 10, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121015-Quarterly-compliance-report-of-the-Corp.-Gov.30-09-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.30-09-2012<\/a><\/p>\n<p>October 09, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121004-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 04, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121003-Rising-Funds-_-Fixation-of-Book-Closure-Date.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Rising Funds &amp; Fixation of Book Closure Date<\/a><\/p>\n<p>October 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120927-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>September 27, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120813-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2012..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2012<\/a><\/p>\n<p>August 13, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120807-Intimation-Restructuring-Interim-Dividend-_-Record-Date-SPIL-3-8-12.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation Restructuring, Interim Dividend &amp; Record Date 3-8-12<\/a><\/p>\n<p>August 06, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120703-Quarterly-compliance-report-of-the-Corp.-Gov.30-06-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.30-06-2012<\/a><\/p>\n<p>July 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120416-Clause-47-c-of-the-Listing-Agreement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Compliance as per Clause 47 (c) as on 31.03.2012<\/a><\/p>\n<p>April 24, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120403-Quarterly-compliance-report-of-the-Corp.-Gov.31-03-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-03-2012.pdf<\/a><\/p>\n<p>April 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120130-Notice-of-Board-Meeting-for-quarter-end-31-12-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2011<\/a><\/p>\n<p>January 30, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120111-Quarterly-compliance-report-of-the-Corp.-Gov.31-12-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-12-2010<\/a><\/p>\n<p>January 11, 2012<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2011&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Notice to acquire all the outstanding shares in Taro Pharma<\/p>\n<p>October 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20111018-Notice-of-Board-Meeting-for-quarter-end-30-09-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2011<\/a><\/p>\n<p>October 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20111013-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>October 13, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110927-Acquisition-of-Shares-_-Takeovers-code-intimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Shares &amp; Takeovers code intimation<\/a><\/p>\n<p>September 27, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110919-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>September 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110905-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2011<\/a><\/p>\n<p>September 05, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110819-SPIL-Proxy-Form-_-Attendance-Slip.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip<\/a><\/p>\n<p>August 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110715-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>July 15, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110705-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>July 05, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110511-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>May 11, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110511-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>May 11, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110819-Notice-of-Nineteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Nineteenth Annual General Meeting<\/a><\/p>\n<p>April 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110330-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 30, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110218-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>February 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110128-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>January 28, 2011<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2010&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20101112-Result-of-the-Postal-Ballot.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Result of the Postal Ballot<\/a><\/p>\n<p>November 12, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20101111-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>November 11, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100923-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>September 30, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/18th-AGM-Chairman-Speech-Sep-2010-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">18th AGM Chairman Speech<\/a><\/p>\n<p>September 26, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100924-Notice-of-Proceedings-18th-AGM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Proceedings Eighteenth AGM<\/a><\/p>\n<p>September 24, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100924-Notice-Split-of-Shares-fro-Rs.5-to-Re.1-per-share.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice Split of Shares fro Rs.5 to Re.1 per share<\/a><\/p>\n<p>September 24, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100907-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>September 07, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100901-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>September 01, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100819-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2010<\/a><\/p>\n<p>August 19, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100810-Fixation-of-Book-Closure-Date-for-payment-of-Dividend..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Fixation of Book Closure Date for payment of Dividend<\/a><\/p>\n<p>August 10, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100614-Notice-of-Eighteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Eighteenth Annual General Meeting<\/a><\/p>\n<p>June 14, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100901-Security-pledge-revocation-letter-Revoked1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>May 22, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100507-Notice-of-Board-Meeting-for-quarter-end-31-03-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-03-2010<\/a><\/p>\n<p>May 07, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100402-appointed-Shri.-Kal-Sundaram-as-an-additional-Director-on-the-Board.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Appointed Shri. Kal Sundaram, as an additional Director on the Board<\/a><\/p>\n<p>April 02, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100326-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 26, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100104-Quarterly-compliance-report-of-the-Corp.-Gov.-31-12-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 31-12-2009<\/a><\/p>\n<p>January 04, 2010<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2009&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091218-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>December 18, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/20091103-Security-pledge-revocation-letter-Pledged-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>November 03, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091020-Security-pledge-revocation-letter-Revoked-_-Pledged-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>October 20, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091010-Notice-of-Board-Meeting-for-quarter-end-30-09-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2009<\/a><\/p>\n<p>October 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090914-Notice-for-expiry-of-HSR-waiting-period-in-U.S.-for-Taro-Tender-Offer.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice for expiry of HSR waiting period in U.S. for Taro Tender Offer<\/a><\/p>\n<p>September 14, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090912-Acquisition-of-Shares-_-Takeovers-code-intimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Shares &amp; Takeovers code intimation<\/a><\/p>\n<p>September 12, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090912-Notice-of-Proceedings-17th-AGM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Proceedings Seventeenth AGM<\/a><\/p>\n<p>September 12, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/17th-AGM-Chairman-Speech-Sep-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">17th AGM Chairman Speech<\/a><\/p>\n<p>September 11, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090810-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>August 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090711-Notice-of-Seventeenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Seventeenth Annual General Meeting<\/a><\/p>\n<p>July 11, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090702-Quarterly-compliance-report-of-the-Corp.-Gov.-30-06-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 30-06-2009<\/a><\/p>\n<p>July 02, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090530-Outcome-of-Board-meeting-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board meeting 31-03-2009<\/a><\/p>\n<p>May 30, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090420-Details-of-share-holding-in-terms-of-Regulation-83-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Details of share holding, in terms of Regulation 8(3)<\/a><\/p>\n<p>April 20, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090407-Quarterly-compliance-report-of-the-Corp.-Gov.-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 31-03-2009<\/a><\/p>\n<p>April 07, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090731-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2009<\/a><\/p>\n<p>March 31, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090313-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 13, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090210-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>February 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090116-Notice-of-Board-Meeting-for-quarter-end-31-12-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2008<\/a><\/p>\n<p>January 16, 2009<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2008&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20081003-Quarterly-compliance-report-of-the-Corp.-Gov.-30-09-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 30-09-2008<\/a><\/p>\n<p><span>October 03, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/16th-AGM-Chairman-Speech-Sep-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>16th AGM Chairman Speech<\/span><\/a><\/p>\n<p><span>September 06, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080827-Notice-of-Sixteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Notice of Sixteenth Annual General Meeting<\/span><\/a><\/p>\n<p><span>August 27, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080808-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Form of Waiverforgoing the Right to receive the dividend 31-03-2008<\/span><\/a><\/p>\n<p><span>August 08, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080412-Quarterly-compliance-report-of-the-Corp.-Gov.-31-03-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Quarterly compliance report of the Corp. Gov. 31-03-2008<\/span><\/a><\/p>\n<p><span>April 12, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080320-Allotment-of-Equity-Shares-against-conversion-of-further-FCCBs.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Allotment of Equity Shares against conversion of further FCCBs<\/span><\/a><\/p>\n<p><span>March 20, 2008<\/span><\/p>\n<p><span><\/span><\/p>\n<p>[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Statutory Communications<div class=\"sub_stat_input\">\r\n\t<label for=\"\">Search: <\/label><input type=\"text\" class=\"input-medium search-query\" id=\"sub_cmpy_filter\" placeholder=\"\">\r\n<\/div>Scrutinizer Report of Postal Ballot E-voting April 2026 Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon &#038; Co. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-3333","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical<\/title>\n<meta name=\"description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical\" \/>\n<meta property=\"og:description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T14:22:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 \u05d3\u05e7\u05d5\u05ea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\",\"name\":\"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"datePublished\":\"2020-12-14T07:30:23+00:00\",\"dateModified\":\"2026-05-08T14:22:28+00:00\",\"description\":\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors &#8211; Statutory Communications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","og_locale":"he_IL","og_type":"article","og_title":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","og_description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","og_url":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_modified_time":"2026-05-08T14:22:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 \u05d3\u05e7\u05d5\u05ea"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/","url":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/","name":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"datePublished":"2020-12-14T07:30:23+00:00","dateModified":"2026-05-08T14:22:28+00:00","description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/investors-statutory-communications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Investors &#8211; Statutory Communications"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=3333"}],"version-history":[{"count":277,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333\/revisions"}],"predecessor-version":[{"id":18939,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333\/revisions\/18939"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=3333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}